Fig. 1From: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumorsThe tumor-to-blood ratio (of %IA/g) of 211At-A11 on s.c. PC3-PSCA macrotumors plotted versus time after injection. Included for comparison is the tumor-to-blood ratio of 211At-MX35-F(ab’)2, which was shown to be therapeutically efficient on macrotumors in previous studies of ovarian cancer [21]Back to article page